Upcoming events – Ascendis and Lilly hope for growth with pivotal data
Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
Protagonist will need more than perseverance to play in bowel disease
A new analysis of an abandoned trial has resurrected Protagonist's lead asset, but the company has a long way to go and faces some stiff competition.
Why competitive bidding will be a hard task in Medicare
The US government is trying to change the way Medicare reimburses doctors for office-administered drugs – but whether it will succeed is another story.
Heart benefit now a baseline for Invokana and all diabetes drugs
Invokana looking for good showing at American College of Cardiology meeting to improve prospects.
Slowing Acthar sales are a warning about rising patient costs
Acthar's high price tag has led to slowing sales, but it is patients, not payers, who are leading the backlash.
